Verition Fund Management
AKBA icon

Verition Fund Management’s Akebia Therapeutics AKBA Stock Holding History

Verition Fund Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-104,334
Closed -$200K – 3612
2025
Q1 		$200K Buy
+104,334
New +$213K ﹤0.01% 3049
2023
Q4 		– Sell
-55,870
Closed -$63.7K – 2301
2023
Q3 		$63.7K Buy
+55,870
New +$71.8K ﹤0.01% 2163
2022
Q3 		– Sell
-10,673
Closed -$4K – 3029
2022
Q2 		$4K Buy
+10,673
New +$4.48K ﹤0.01% 2263
2018
Q2 		– Sell
-13,739
Closed -$131K – 1054
2018
Q1 		$131K Buy
+13,739
New +$192K 0.01% 1042

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Verition Fund Management's AKBA Position: Q2 2025 in Review

Verition Fund Management sold out of Akebia Therapeutics (AKBA) in Q2 2025, closing a stake of 104,334 shares — an estimated $200K sold.

Verition Fund Management first reported a position in AKBA in Q1 2018 and held it in 4 quarters. The position peaked at $200K in Q1 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q2 2025.

  • Verition Fund Management reported no remaining Akebia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 104,334 Akebia Therapeutics shares in Q2 2025, an estimated $200K.
  • Verition Fund Management first reported a position in Akebia Therapeutics in Q1 2018 and held it in 4 quarters.
  • Verition Fund Management's Akebia Therapeutics position peaked at $200K in Q1 2025.
  • 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.